Icynene Europe Announces Suite of New Product Innovations as Growth Within European Market Continues
24.5.2017 11:45:00 EEST | Business Wire | Press release
Icynene Europe S.P.R.L. today announced the release of several new spray foam products as it continues to experience sustained growth within established markets and expand into new regions.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170524005071/en/
Icynene has introduced a new closed-cell spray foam product featuring HFO blowing agent Opteon 1100™ from Chemours Company, a low-VOC closed-cell spray foam product as well as a low-pressure kit for touch-up and repair work. The product innovation complements Icynene’s move to begin manufacturing within the Czech Republic.
“Continual product innovation and the introduction of several new high-performance insulation products demonstrate that Icynene continues to lead and evolve the spray foam insulation category. Moreover, through fostering key partnerships, we have broadened our recognition and reach across the continent while ensuring our customers remain competitive and successful in their local markets,” said Bertrand Lauret, Director of Icynene for Europe, Africa and the Middle East.
IcyFoam Select – the first HFO spray foam with CE Marketing
IcyFoam
Select is believed to be the first spray foam insulation product that
uses a HFO blowing agent, Opteon 1100™ from the Chemours Company, to
acquire the CE Marketing. IcyFoam Select has been used in the new
BoxPark Croydon development in London. IcyFoam Select was applied in
50mm (two inch) thicknesses on the interior of 70 shipping containers.
The project’s architectural firm selected Icynene and the new HFO
product for Icynene’s strong brand recognition and quality reputation
within the market, the insulation’s thermal insulating qualities, air
sealing qualities as well as for its environmental credentials.
IcyFoam Basic – Low VOC spray foam
Suitable for commercial
and residential construction, new low VOC spray foam innovation, IcyFoam
Basic, offers a 0,027 lambda value, superior adhesion and air sealing
properties. The 40kg/m3 closed-cell spray foam product has
received a CE marking and an ‘E’ fire class rating.
IcyFoam QuickFill – Spray foam repair kits
IcyFoam QuickFill
spray foam insulation repair kits are intended as an accompaniment to
insulate and air seal hard-to-reach and small areas that larger,
high-pressure systems are unable to reach. Designed for quick and easy
use, the kits are light-weight for easy portability. Each kit is
equipped with a canister of foam product, a PU cleaner, foam gun
applicator and water spray bottle.
Manufacturing to commence in Czech Republic
Icynene Europe
will begin to manufacture its European spray foam insulation products in
the Czech Republic in an effort to streamline production and logistic
shipping practices within the region. Manufacturing will begin in spring
to meet the increase in demand during the summer period.
About Icynene
Established in 1986, Icynene’s portfolio of
industry leading light density open cell and medium density closed cell
SPF solutions are both insulation and air barrier materials for improved
indoor air quality and reduced energy costs making Icynene the smart
choice for builders, architects, building owners, and homeowners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170524005071/en/
Contact information
Icynene Marketing Communications
Anthony Naimo, 1-800-758-7325 x215
media@icynene.com
www.icynene.eu
www.icynene.co.uk
www.icynene.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Frasca Pilatus PC-12 PRO Flight Training Device Receives FOCA Qualification21.4.2026 17:05:00 EEST | Press release
Frasca International, Inc., a FlightSafety International company and global leader in flight simulation, today announced that its Pilatus PC-12 PRO Flight Simulation Training Device (FSTD) received Level 2 Flight Training Device (FTD2) and Flight and Navigation Procedures Trainer (FNPT II) qualification from Switzerland’s Federal Office of Civil Aviation (FOCA). Frasca is the first to develop a PC-12 PRO training device. The device equipped with Garmin’s G3000 PRIME Avionics suite is installed at Pilatus Aircraft Ltd headquarters in Stans, Switzerland, where it will support training for the next generation of PC-12 pilots. The qualification enables pilots to complete a wide range of instruments, procedural and advanced systems training in a highly immersive environment that mirrors the capabilities of the aircraft. “The PC-12 PRO leads the way with advanced features, and we’re proud to produce a state-of-the-art simulator that allows pilots to seamlessly transition from the FTD to the
Frasca Pilatus PC-12 PRO Flight Training Device Receives FOCA Qualification21.4.2026 17:05:00 EEST | Press release
Frasca International, Inc., a FlightSafety International company and global leader in flight simulation, today announced that its Pilatus PC-12 PRO Flight Simulation Training Device (FSTD) received Level 2 Flight Training Device (FTD2) and Flight and Navigation Procedures Trainer (FNPT II) qualification from Switzerland’s Federal Office of Civil Aviation (FOCA). Frasca is the first to develop a PC-12 PRO training device. The device equipped with Garmin’s G3000 PRIME Avionics suite is installed at Pilatus Aircraft Ltd headquarters in Stans, Switzerland, where it will support training for the next generation of PC-12 pilots. The qualification enables pilots to complete a wide range of instruments, procedural and advanced systems training in a highly immersive environment that mirrors the capabilities of the aircraft. “The PC-12 PRO leads the way with advanced features, and we’re proud to produce a state-of-the-art simulator that allows pilots to seamlessly transition from the FTD to the
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting21.4.2026 17:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that full results from the Phase 3 pivotal study evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) will be featured as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago. “The positive Phase 3 frontMIND results for tafasitamab in patients with newly diagnosed diffuse large B-cell lymphoma highlight Incyte’s continued focus on advancing novel differentiated approaches with the potential to meaningfully impact patients,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “We look forward to sharing the full data at ASCO, and to progressing our pipeline.” Presentation details: frontMIND: Phase 3 Study of tafasitamab (Tafa) Plus lenalidomide (Len) and R-CHOP for Patients (pts) with Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) (Abstract #7000. Session: Oral Abstract Session
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting21.4.2026 17:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that full results from the Phase 3 pivotal study evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) will be featured as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago. “The positive Phase 3 frontMIND results for tafasitamab in patients with newly diagnosed diffuse large B-cell lymphoma highlight Incyte’s continued focus on advancing novel differentiated approaches with the potential to meaningfully impact patients,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “We look forward to sharing the full data at ASCO, and to progressing our pipeline.” Presentation details: frontMIND: Phase 3 Study of tafasitamab (Tafa) Plus lenalidomide (Len) and R-CHOP for Patients (pts) with Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) (Abstract #7000. Session: Oral Abstract Session
Andersen Global Strengthens West Africa Platform with the Addition of Member Firm in Ghana21.4.2026 16:30:00 EEST | Press release
Andersen Global continues its expansion across Africa, with Lima Partners joining as a member firm and introducing the Andersen name in Ghana. Established in 2014 and headquartered in Accra, Andersen in Ghana is led by Managing Partner Daniel Addo Okoe. The firm provides a full range of professional services, including tax advisory, regulatory compliance, accounting and advisory, transfer pricing, payroll administration, immigration, and company secretarial services to both local and international clients operating in Ghana and the wider West African region. “Becoming a member firm of Andersen Global marks a significant milestone for our organization,” said Kwame Amporful, senior partner of Andersen in Ghana. “Our clients will benefit from enhanced cross-border capabilities while continuing to receive practical, high-quality advisory services tailored to the Ghanaian market.” “Ghana plays a vital role in facilitating cross-border trade and investment within West Africa,” added Mark L.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
